Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 3:49 PM
Ignite Modification Date:
2025-12-25 @ 1:56 PM
NCT ID:
NCT00193492
Group ID:
EG001
Title:
Rituximab/Bevacizumab
Description:
All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
Bevacizumab
Rituximab
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
8
Serious Number At Risk:
29
Other Number Affected:
29
Other Number At Risk:
29
Study:
NCT00193492
Results Section:
NCT00193492
Adverse Events Module:
NCT00193492